Celgene
Celgene’s ozanimod meets endpoints in Phase II ulcerative colitis trials
March 21, 2016Research and Development, Sales and Marketing Celgene
Celgene International SÃ rl, a Celgene subsidiary, has announced additional data of exploratory endpoints from a Phase II trial of ozanimod …
Wales approve pancreatic cancer drug for use despite NICE rejection in England
March 18, 2016Medical Communications, Research and Development Abraxane, Celgene, England, NHS, NICE, Wales, approval
Celgene (Nasdaq: CELG) has announced that Abraxane, in combination with gemcitabine, will continue to be an available treatment option for …
Allergan files ANDA for generic version of Celgene’s breast cancer treatment
March 18, 2016Business Services, Medical Communications, Sales and Marketing Abraxane, Allergan, Celgene, breast cancer, generic
Allergan (NYSE: AGN) said it is seeking regulatory approval for a generic version of biotech firm Celgene’s (Nasdaq: CELG) breast …
Two Celgene cancer drugs approved in Ireland
March 1, 2016Research and Development, Sales and Marketing Abraxane, Cancer, Celgene, Revlimid, imnovid
Irish regulators have recommended two cancer treatments from Celgene: Imnovid (pomalidomide), in combination with dexamethasone, for previously-treated relapsed and refractory …
Big pharma joins President Obama’s cancer ‘moonshot’
January 13, 2016Research and Development Amgen, Cancer, Celgene, National Immunotherapy Coalition, President Barack Obama, US, moonshot
Celgene and Amgen are among the large biopharma companies that have agreed to join the National Immunotherapy Coalition (NIC), a …
Mark Alles is new chief executive of Celgene
January 12, 2016Manufacturing and Production, Research and Development, Sales and Marketing Celgene, Mark Alles
Celgene president and chief operating officer Mike Alles has been promoted to the top job after an executive restructure at …
Celgene settles Revlimid patent dispute
December 23, 2015Manufacturing and Production, Research and Development, Sales and Marketing Celgene, India, Natco, Revlimid, lenalidomide, patents
Celgene has settled its litigation with Natco Pharma, over the patents for Revlimid, opening the door to increased generic competition …
Cancer and MS drugs approved in Scotland
December 9, 2015Sales and Marketing Celgene, Copaxone, Novartis, SMC, Scottish Medicines Consortium, Tevaq, ceritinib, glatiramer acetate, lenalidomide, lung cancer, multiple myeloma, multiple sclerosis, revlimis, zykadia
The Scottish Medicines Consortium (SMC) has approved three new treatments for lung cancer, multiple sclerosis and multiple myeloma, from Novartis, …
Celgene’s Vidaza earns wider approval
November 2, 2015Sales and Marketing Celgene, European Commission, Vidaza, acute myeloid leukaemia, azacitidine, leukaemia
Swiss firm Celgene has been given approval by the European Commission to extend its marketing authorisation for the cancer treatment …
NICE says Celgene’s Abraxane is ‘too expensive for pancreatic cancer’
September 17, 2015Sales and Marketing Abraxane, Celgene, NICE, Pancreatic cancer
NICE has decided not to recommend Abraxane (nab-paclitaxel) by Celgene in combination with gemcitabine for adults with metastatic pancreatic cancer.In …
Celgene threatens to scale back UK clinical trial investment after CDF snub
September 4, 2015Research and Development, Sales and Marketing Cancer, Cancer Drugs Fund, Celgene, Revlimid, british nhs
One of the world’s leading pharma companies in oncology is considering whether to continue investing in clinical trials in the …
Working Life: Celgene’s Lee Heeson
August 3, 2015Medical Communications, Sales and Marketing Celgene, Lee Heeson
How did you find your way into your current role?My career has progressed from ‘carrying the bag’ for GlaxoSmithKline in …
Celgene to acquire Receptos in $7.2bn deal
July 15, 2015Sales and Marketing Celgene, Crohn's, Crohn’s disease, Receptos, acquisitions, crohn's disease, mergers, multiple sclerosis, ozanimod, relapsing multiple sclerosis, ulcerative colitis
Celgene has boosted its immune and inflammatory disease pipeline with the purchase of the biopharma company Receptos for $7.2 billion. …
Celgene enters 10-year $1 billion pact with Juno
June 30, 2015Research and Development, Sales and Marketing CAR-T, Celgene, Chimeric Antigen Receptor Technology, Juno, T Cell Receptor, TCR, brett wells
Celgene has invested $1 billion into Juno Therapeutics as part of a 10-year partnership aiming to study cures for cancer …
NICE rejects Otelza but SMC recommends it
June 11, 2015Sales and Marketing Astellas, Celgene, NHS, NICE, SMC, Xtandi, otezla
Draft guidance issued by NICE has seen rejections for products including Celgene’s Otelza and Astellas Pharma’s Xtandi, and a call …
Latest content
FibroFind appoints Lee Borthwick as CEO
